Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Completed · Phase 2
Conditions studied: Bladder Cancer
In brief
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving erlotinib after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well erlotinib works when given before and after surgery in treating patients with muscle-invasive bladder cancer.
Key facts
- Study ID
- NCT00380029
- Run by
- UNC Lineberger Comprehensive Cancer Center
- People needed
- 27
- Starts
- 2006-05-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2017-07-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.